Dendritic cell defects in patients with cancer: mechanisms and significance
/in Dendritic Cells, International Publications /von 2006-01-05 / Breast Cancer Res. 2006;8(1):101Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
/in Chronic Leukemia, Dendritic Cells, International Publications /von 2006-01-01 / Cytotherapy 2006;8(4):318-26Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Cytotherapy 2006;8(3):277-89Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37Genetically modified dendritic cells for therapeutic immunity
/in Dendritic Cells, International Publications /von 2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-8Vaccine strategies to treat lymphoproliferative disorders
/in Chronic Leukemia, Dendritic Cells, International Publications, Malignant Lymphoma, Multiple Myeloma /von 2005-12-01 / Pathology 2005 Dec;37(6):534-50Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-68Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer
/in Dendritic Cells, Hyperthermia, International Publications /von 2005-11-15 / Immunol. Lett. 2006 Mar;103(2):142-8Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6B):4225-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de